Literature DB >> 17404263

Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D.

Daniel Peter1, S L Catherine Jin, Marco Conti, Armin Hatzelmann, Christof Zitt.   

Abstract

Type 4 phosphodiesterases (PDE4) are critical regulators in TCR signaling by attenuating the negative constraint of cAMP. In this study, we show that anti-CD3/CD28 stimulation of human primary CD4(+) T cells increases the expression of the PDE4 subtypes PDE4A, PDE4B, and PDE4D in a specific and time-dependent manner. PDE4A and PDE4D mRNAs as well as enzyme activities were up-regulated within 5 days, PDE4B showed a transient up-regulation with highest levels after 24 h. The induction was shown to be independent of different stimulation conditions and was similar in naive and memory T cell subpopulations. To elucidate the functional impact of individual PDE4 subtypes on T cell function, we used PDE4 subtype-specific short-interfering RNAs (siRNAs). Knockdown of either PDE4B or PDE4D inhibited IL-2 release 24 h after stimulation (time point of maximal IL-2 concentrations) to an extent similar to that observed with the panPDE4 inhibitor RP73401 (piclamilast). Substantial amounts of IFN-gamma or IL-5 were measured only at later time points. siRNA targeting PDE4D showed a predominant inhibitory effect on these cytokines measured after 72 h. However, the inhibition of all cytokines was most effective when PDE4 siRNAs were applied in combination. Although the effect of PDE4 inhibition on T cell proliferation is small, the PDE4D-targeting siRNA alone was as effective as the panPDE4 inhibitor, whereas PDE4A or PDE4B siRNAs had hardly an effect. In summary, individual PDE4 subtypes have overall nonredundant, but complementary, time-dependent roles in propagating various T cell functions and PDE4D is the form likely playing a predominant role.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17404263     DOI: 10.4049/jimmunol.178.8.4820

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  New insights into PDE4B inhibitor selectivity: CoMFA analyses and molecular docking studies.

Authors:  Sara Guariento; Olga Bruno; Paola Fossa; Elena Cichero
Journal:  Mol Divers       Date:  2015-08-20       Impact factor: 2.943

Review 2.  PDE4 inhibitors: current status.

Authors:  D Spina
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

3.  Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma.

Authors:  S-L Catherine Jin; Sho Goya; Susumu Nakae; Dan Wang; Matthew Bruss; Chiaoyin Hou; Dale Umetsu; Marco Conti
Journal:  J Allergy Clin Immunol       Date:  2010-11-03       Impact factor: 10.793

Review 4.  Regulation of the T Cell Response by CD39.

Authors:  Maisa C Takenaka; Simon Robson; Francisco J Quintana
Journal:  Trends Immunol       Date:  2016-05-25       Impact factor: 16.687

Review 5.  Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.

Authors:  Klaus F Rabe
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 6.  Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension.

Authors:  Patrick Crosswhite; Zhongjie Sun
Journal:  J Hypertens       Date:  2010-02       Impact factor: 4.844

7.  The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma.

Authors:  Dave Singh; Frank Petavy; Alex J Macdonald; Aili L Lazaar; Brian J O'Connor
Journal:  Respir Res       Date:  2010-03-01

8.  PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER.

Authors:  Amanda G Vang; Shlomo Z Ben-Sasson; Hongli Dong; Barbara Kream; Michael P DeNinno; Michelle M Claffey; William Housley; Robert B Clark; Paul M Epstein; Stefan Brocke
Journal:  PLoS One       Date:  2010-08-09       Impact factor: 3.240

9.  Galectin-8 induces apoptosis in Jurkat T cells by phosphatidic acid-mediated ERK1/2 activation supported by protein kinase A down-regulation.

Authors:  Andrés Norambuena; Claudia Metz; Lucas Vicuña; Antonia Silva; Evelyn Pardo; Claudia Oyanadel; Loreto Massardo; Alfonso González; Andrea Soza
Journal:  J Biol Chem       Date:  2009-03-09       Impact factor: 5.157

10.  Phosphodiesterase 4D single-nucleotide polymorphism 83 and cognitive dysfunction in carotid endarterectomy patients.

Authors:  Eric J Heyer; Joanna L Mergeche; Justin T Ward; Hani R Malone; Christopher Kellner; Samuel S Bruce; E Sander Connolly
Journal:  Neurosurgery       Date:  2013-11       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.